UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events
On April 9, 2024, Viracta Therapeutics, Inc. (the “Company”) received a written notice from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with Nasdaq's Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Select Market, as the closing bid price of the Company’s common stock had met or exceeded $1.00 per share for a minimum of ten consecutive business days and that the matter was now closed.
As previously disclosed on November 15, 2023, the Company received a written notice from Nasdaq indicating that, for the last 30 consecutive business days, the minimum bid price of the Company’s common stock had been below the $1.00 per share minimum requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Company had 180 calendar days, or until May 13, 2024, to regain compliance with the Minimum Bid Price Requirement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Viracta Therapeutics, Inc |
|
|
|
|
Date: |
April 9, 2024 |
By: |
/s/ Mark Rothera |
|
|
|
Mark Rothera |
Document And Entity Information |
Apr. 09, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Apr. 09, 2024 |
Entity Registrant Name | Viracta Therapeutics, Inc. |
Entity Central Index Key | 0001061027 |
Entity Emerging Growth Company | false |
Entity File Number | 000-51531 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 94-3295878 |
Entity Address, Address Line One | 2533 S. Coast Hwy. 101, Suite 210 |
Entity Address, City or Town | Cardiff |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 92007 |
City Area Code | (858) |
Local Phone Number | 400-8470 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.0001 per share |
Trading Symbol | VIRX |
Security Exchange Name | NASDAQ |
MJ7M\7/)^'?621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X% -8?2
M0$3;8T.P6BP^0"X99K>]9!:G
)U7 5Z3A@ XQ\R8S[L-4M@G5C"KDSYU'O<&N! MV:IRODWH4L (]S*N42YTKK\]15P+( M>3R]#$-8OKY9" -/<##%E$>UL&XQ;.S3@Z;7B4X!=YKT/[+7?Q>!_ M@[L8GCW_36RP8EG#4U@8]1?=T*!41KG, 6XV7H$#RWSHD-I#1]]T^YD%+7L3 M&RC/#9:>=V 8=PZ,[QNGL DGLXIE[\@+)XO['8(N"B*29>O9?EW.2?0N5#^: M^69"7=X:M#HID1PI+HP;]R#O_KJ"&':X>L.X4H"Z*"\<4!J+5^8*3+A0-[R9 MS,K?+K+VM4?3Q14\<&D8<8B&Y8AK\N]5JMWXO;O^<](7*Z?&Z<_%)C M#Y:W%R1CY-^%"D9?2/J5Y^CSY^;FXU<>OU-Q-=A^&T=-*V;2*<,1':- ;
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